We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

85 hedge funds and large institutions have $11.3M invested in Celldex Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 1.97% → 1.99% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

11% less funds holding

Funds holding: 95 → 85 (-10)

22% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 27

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

51% less capital invested

Capital invested by funds: $23.2M → $11.3M (-$11.9M)

Holders
85
Holders Change
-10
Holders Change %
-10.53%
% of All Funds
1.89%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
21
Reduced
27
Closed
20
Calls
$13K
Puts
–
Net Calls
+$13K
Net Calls Change
+$15K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$424K
2
AFM
Anson Funds Management
Texas
+$403K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$94.1K
4
SWP
Stratos Wealth Partners
Ohio
+$78.6K
5
TCMG
TSP Capital Management Group
New Jersey
+$77.6K

Top Sellers

1
BlackRock
BlackRock
New York
-$633K
2
Millennium Management
Millennium Management
New York
-$474K
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$347K
4
Deutsche Bank
Deutsche Bank
Germany
-$233K
5
GCP
GSA Capital Partners
United Kingdom
-$158K
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
76
ProShare Advisors
Maryland
– -$30K -4,416 Closed
Bank of America
77
Bank of America
North Carolina
– -$10.5K -2,139 -96%
Principal Financial Group
78
Principal Financial Group
Iowa
– -$9K -1,377 Closed
LP
79
LMR Partners
United Kingdom
– -$9K -1,363 Closed
FWCM
80
Ferguson Wellman Capital Management
Oregon
– -$7K -1,073 Closed
Koshinski Asset Management
81
Koshinski Asset Management
Illinois
– -$6K -947 Closed
TSS
82
Two Sigma Securities
New York
– -$5K -806 Closed
Man Group
83
Man Group
United Kingdom
– -$5K -733 Closed
BWP
84
BSW Wealth Partners
Colorado
– -$5K -679 Closed
Barclays
85
Barclays
United Kingdom
– -$2.27K -463 -99%
IP
86
Intellectus Partners
California
– -$2K -267 Closed
FANJ
87
Financial Architects (New Jersey)
New Jersey
– -$295 -60 -29%
CF
88
Centaurus Financial
California
– -$11 -2 Closed
ASN
89
Advisory Services Network
Georgia
– +$5 +1 +6%
AIC
90
Ameritas Investment Company
Nebraska
– +$64 +13 New
Royal Bank of Canada
91
Royal Bank of Canada
Ontario, Canada
– +$142 +29 +223%
OIA
92
OneDigital Investment Advisors
Kansas
– +$162 +33 New
1 2 3
4

CLDX Hedge Fund Activity: Q4 2018 in Review

85 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2018, worth a combined $11.3M — down 51% from $23.2M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CLDX and 10 opened new positions — a net loss of 10 holders — while 27 trimmed existing stakes and 21 added.

The largest buyer was Renaissance Technologies, adding an estimated $424K. The largest seller was BlackRock, cutting an estimated $633K.

  • 85 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2018, down from 95 in Q3 2018.
  • Funds reported $11.3M of Celldex Therapeutics stock for Q4 2018, down 51% quarter-over-quarter.
  • 10 funds opened new Celldex Therapeutics positions in Q4 2018 and 20 closed out, a net change of -10 holders.
  • The largest Celldex Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $424K added.
  • The largest Celldex Therapeutics seller in Q4 2018 was BlackRock, an estimated $633K sold.

Based on aggregated 13F filings for Q4 2018.